Investigators showed that sequencing cell-free DNA could detect microsatellite instability, structural rearrangements, and clonal hematopoiesis in patients with metastatic disease.
A phylogenetic analysis that included multiple samples per patient suggests overlapping driver mutations make their way into multiple metastases in each patient.
A new trial has compared the two most prominent tests, showing that both have clear predictive ability, but leaving several other questions unanswered so far.
Exome sequencing on tumors from metastatic, castration-resistant prostate cancer cases responding to immunotherapy led to homologous recombination defects.
In a pan-cancer analysis, Lynch syndrome genes were mutated more often than anticipated in tumors with high or intermediate levels of microsatellite instability.
Informaticians at Spain's National Cancer Research Centre develop a methodology for evaluating likely drug efficacy based on specific patient genotypes.
